Table 2.
Targeting pyroptosis in breast cancer-currently available pharmaceutical agents.
| Pyroptosis inducers | Cell lines | Pyroptosis pathways | Years |
|---|---|---|---|
| Omega-3 docosahexaenoic acid [129] | MDAMB231, 4T1 | Caspase-1/GSDMD | 2018 |
| hUCMSCs [130] | MCF7 | NLRP1 or caspase-4 | 2020 |
| Metformin [131] | MCF7 | Caspase-3/GSDME | 2020 |
| Nobiletin [132] | MCF7, BT549 | Caspase-1 | 2021 |
| Tetraarsenic hexoxide [69] | HS578T, MDAMB231 | Caspase-3/GSDME | 2021 |
| Triclabendazole [133] | MCF7, MDAMB231 | Caspase-3/GSDME | 2021 |
| Cadmium [134] | MDAMB231 | Caspase-3/GSDME | 2021 |
| Dihydroartemisinin [135] | MCF7, MDAMB231 | Caspase-3/GSDME | 2021 |
| Cetuximab [136] | MDAMB231, MDAMB468 | GSDME | 2021 |
| Polyl:C [137] | HS578T, BT549 | Caspase-3/GSDME | 2021 |
| Spatholobus suberectus Dunn [138] | MDAMB231, BT549, 4T1 | GSDME | 2021 |
| Trimethylamine N-oxide [139] | 66cl4 | Caspase-3/GSDME | 2022 |
| 3-acyl isoquinolin-1(2H)-one [140] | MCF7, MDAMB231 | Caspase-3/GSDME | 2022 |
| CDK inhibitors [141] | MDAMB231, BT549, 4T1 | Caspase-3/GSDME | 2022 |
| Bacterial outer membrane vesicles [142] | 4T1 | Caspase-1/GSDMD | 2022 |
| Hirsutinolide natural product R001 [143] | MDAMB231, MDAMB468 | Caspase-1/GSDMD | 2022 |
| US-enhanced enzyodynamic tactics [144] | 4T1 | NLRP3/GSDMD | 2022 |